De-immunized MOG (poly)peptide constructs

Details De-immunized MOG (poly)peptide constructs De-immunized MOG (poly)peptide constructs

2008-01-29

2008-01-29

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S008100, C514S012200, C530S350000, C530S402000

Reexamination Certificate

active

07323440

ABSTRACT:
The present invention relates to a (poly)peptide construct consisting of at least two domains of at least two pluralities of domains wherein one of said domains or pluralities of domains comprises a de-immunized autoreactive antigen or (a) fragment(s) thereof specifically recognized by the Ig receptors of an autoreactive B-cells and wherein a/the further domain or plurality of domains comprises an effector molecule capable of interacting with and/or of activating NK-cells, T-cells, macrophages, monocytes and/or granulocytes. Preferably, said (poly)peptide construct consisting of at least two domains comprises a de-immunized autoreactive antigen or (a) fragment which is MOG or (a) fragment(s) thereof and a second domain comprising an effector molecule is an anti-CD3 receptor or an Fc-part of an immunoglobulin. The invention also relates to compositions comprising the compounds of the invention. Described is also the use of the afore-mentioned (poly)peptide construct and further compounds for the preparation of a pharmaceutical composition for the treatment and/or prevention of an autoimmune disease. In addition, the present invention relates to method for treating, ameliorating and/or preventing of an autoimmune disease.

REFERENCES:
patent: WO 95/24220 (1995-09-01), None
patent: WO 99/23867 (1999-05-01), None
patent: WO 00/01732 (2000-01-01), None
patent: WO 00/01732 (2000-01-01), None
patent: WO 01/02439 (2001-01-01), None
patent: WO 02/16414 (2002-02-01), None
Min et al., “Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon gamma-mediated splenic anergy”,Journal of Experimental Medicine, vol. 188, No. 11, Dec. 7, 1998, pp. 2007-2017, XP002131535, ISSN: 0022-1007.
Kuchroo et al., “A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse cell repertoire”,Journal of Immunology, vol. 153, No. 7, 1994, pp. 3326-3336, XP002206876, ISSN: 0022-1767.
Bai et al., “The Heat-Stable Antigen Determines Pathogenicity of Self-Reactive T Cells in Experimental Autoimmune Encephalomyelitis”,Journal of Clinical Investigation, vol. 105, No. 9, May 2000, pp. 1227-1232, XP002944025, ISSN: 0021-9738.
Cross et al., “Long-Term Inhibition of Murine Experimental Autoimmune Encephalomyelitis Using CTLA-4-FC Supports a Key Role for DC28 Costimulation”,Journal of Clinical Investigation, vol. 95, No. 6, Jun. 1995, pp. 2783-2789, XP009019724, ISSN: 0021-9738.
Link et al., “Production and Characterization of a Bispecific IgG Capable of Inducing T-Cell-Mediated Lysis of Malignant B Cells”,Blood, vol. 81, No. 12, Jun. 15, 1993, pp. 3343-3349, XP002900864, ISSN: 0006-4971.
Schroeder et al., “A recombinant bispecific single chain antibody CD19XCD3 induces rapid B cell lymphoma-directed cytotoxicity of unstimulated human T cells”,Blood, vol. 92, No. 10, Nov. 15, 1998, p. 511A, XP002115457, ISSN: 0006-4971.

Affiliated with

Also associated with

Rating

De-immunized MOG (poly)peptide constructs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with De-immunized MOG (poly)peptide constructs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and De-immunized MOG (poly)peptide constructs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2774956